Our top pick for
ADMA Biologics, Inc is a biotechnology business based in the US. ADMA Biologics shares (ADMA) are listed on the NASDAQ and all prices are listed in US Dollars. ADMA Biologics employs 313 staff and has a trailing 12-month revenue of around USD$40.3 million.
Since the stock market crash in March caused by coronavirus, ADMA Biologics's share price has had significant negative movement.
Its last market close was USD$2.24, which is 38.96% down on its pre-crash value of USD$3.67 and 54.48% up on the lowest point reached during the March crash when the shares fell as low as USD$1.45.
If you had bought USD$1,000 worth of ADMA Biologics shares at the start of February 2020, those shares would have been worth USD$763.10 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$558.61.
|Latest market close||USD$2.24|
|52-week range||USD$1.45 - USD$4.79|
|50-day moving average||USD$2.075|
|200-day moving average||USD$2.6006|
|Wall St. target price||USD$8.29|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.243|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-24)||21.08%|
|1 month (2020-10-30)||12.56%|
|3 months (2020-09-01)||-6.67%|
|6 months (2020-06-01)||-26.80%|
|1 year (2019-11-29)||-52.84%|
|2 years (2018-11-30)||-57.50%|
|3 years (2017-12-01)||-24.83%|
|5 years (2015-12-01)||-75.63%|
|Revenue TTM||USD$40.3 million|
|Gross profit TTM||USD$-10,155,155|
|Return on assets TTM||-21.17%|
|Return on equity TTM||-124.48%|
|Market capitalisation||USD$173 million|
TTM: trailing 12 months
There are currently 12.9 million ADMA Biologics shares held short by investors – that's known as ADMA Biologics's "short interest". This figure is 8.3% down from 14.1 million last month.
There are a few different ways that this level of interest in shorting ADMA Biologics shares can be evaluated.
ADMA Biologics's "short interest ratio" (SIR) is the quantity of ADMA Biologics shares currently shorted divided by the average quantity of ADMA Biologics shares traded daily (recently around 2.3 million). ADMA Biologics's SIR currently stands at 5.59. In other words for every 100,000 ADMA Biologics shares traded daily on the market, roughly 5590 shares are currently held short.
However ADMA Biologics's short interest can also be evaluated against the total number of ADMA Biologics shares, or, against the total number of tradable ADMA Biologics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ADMA Biologics's short interest could be expressed as 0.13% of the outstanding shares (for every 100,000 ADMA Biologics shares in existence, roughly 130 shares are currently held short) or 0.1721% of the tradable shares (for every 100,000 tradable ADMA Biologics shares, roughly 172 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against ADMA Biologics.
Find out more about how you can short ADMA Biologics stock.
We're not expecting ADMA Biologics to pay a dividend over the next 12 months.
Over the last 12 months, ADMA Biologics's shares have ranged in value from as little as $1.45 up to $4.79. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ADMA Biologics's is 2.0209. This would suggest that ADMA Biologics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company distributes its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.